<p><strong>New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's disease</strong></p><p><strong>Expanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's</strong></p>

Maryland-based biotechnology leader, Elixirgen Scientific, Inc., launches Alzheimer’s Disease Panel, strengthening their commitment to quality and innovation in disease research and drug discovery.

Reducing neuroinflammation with Photobiomodulation

Rodriguez brings healthcare leadership experience to fast-growing, digital cognitive assessment platform used by thousands of physicians and providers

Grant supports development and use study for puzzle created for the Alzheimer's and dementia populations.

"He deserved options. We all do." Mississippi woman honors her father on World Alzheimer's Day

Already compatible with Fitbit smartwatches, the personal health management and remote monitoring technology is now also available for Apple smartwatches

Sinceri Senior Living (formerly JEA Senior Living), a large senior living management company with operations across the U.S., announced today it has acquired management contracts of another eight senior housing communities.

Following recent FDA approval of Biogen's Alzheimer antibody drug ADUHELM (TM), targeting oligomers of amyloid beta, Galimedix aims for first patients with its GAL-201 oral small molecule drug within one year.

The team from Discovery Senior Living raised $29,600 as part of the Sixth Annual Cycle4ALZ event, hosted by the Brevard Alzheimer's Foundation. Every dollar will go to help fund crucial Alzheimer's care and service programs.

State-of-the-Art ALF combines the resources and expertise to help residents with Dementia and Alzheimer's

Ionize. Filter. Breathe. Repeat.

Ionize. Filter. Breathe. Repeat.

Ionize. Filter. Breathe. Repeat.

Ionize. Filter. Breathe. Repeat.

Ionize. Filter. Breathe. Repeat.

Certified dementia care practitioner, educator and 30-year professional Dawn Platt will assume the newly created role of Director of Memory Care Programs, a position which includes leadership of the company's nationally recognized SHINE® Memory Care Program.

This year's event will feature renowned scientists and an opening meditation with special guest Deepak Chopra, M.D.

The proprietary memory care program's curriculum was recognized by the Alzheimer's Association® for incorporating evidence-based recommendations and best practices for person-centered care, engagement and activities of daily living, communication protocols and more.

The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine.